Dr. Aaron Scott is an Assistant Professor of Medicine who primarily treats patients with gastrointestinal (GI) cancers.
Dr. Scott received his medical degree from The University of Arizona College of Medicine in Tucson, Arizona. He completed both his Internal Medicine residency and Hematology/Oncology fellowship at the University of Colorado in Denver, Colorado. He served as the Chief Medical Oncology Fellow in 2015.
He specializes in cancers of the GI tract, which include colon cancer, rectal cancer, anal cancer, esophageal cancer, stomach cancer, liver cancer, and pancreatic cancer. His particular interests are in clinical trial development and laboratory research investigating new agents to improve outcomes in patients with GI cancers.
He is board certified by the American Board of Internal Medicine in Medical Oncology and Internal Medicine.
Dr. Scott is a member of the Gastrointestinal (GI) Oncology Multidisciplinary Program at The University of Arizona Cancer Center. This comprehensive program includes weekly multidisciplinary tumor board meetings, bi-monthly research meetings, and research collaborations with the Developmental Therapeutics/Phase 1 Program. In addition, he is involved in developing research projects across specialities including Radiation Oncology, Surgical Oncology, Radiology, and Pathology. Dr. Scott is also the site Principal Investigator of the Academic GI Cancer Consortium (AGICC), which is a nationwide collaborative research group dedicated to finding better treatment options for patients with GI cancer. Dr. Scott is interested in the development of novel therapeutic strategies to treat and prevent colorectal cancer in young adults.
- Scott AJ, Song EK, Bagby S et al. “Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and xenograft mouse model.” BMC Cancer. Submitted and under review. 2016
- Scott AJ, Lieu CH, Messersmith WA. “Therapeutic approaches to RAS mutation.” The Cancer Journal 2016; 22 (3): 165-174
- O’Neil BH, Scott, A*, Ma WW et al. “A phase II/III randomized study to compare the efficacy and safety of rigosertib and gemcitabine versus gemcitabine alone in previously untreated metastatic pancreatic cancer.” Ann Oncol (2015) doi: 10.1093/annonc/mdv264
- Scott A, Messersmith WA, Jimeno A. “Apatinib: a promising oral anti-angiogenic in the treatment of solid tumors.” Drugs of Today 2015; 51(4): 223-229
- Scott A, Messersmith WA, Jimeno A et al. “Panitumumab in the treatment of colon cancer: a biomarker dilemma.” Drugs of Today 2014; 50(10): 679-90
- Scott A, Leong S, Messersmith WA et al. “A moving target: challenges in treating BRAF-mutant colorectal cancer.” Colorectal Cancer 2013; 2(3), 1-8
- Scott A, Amaria RN, Lewis K. “Adjuvant peg-interferon alfa-2b therapy in stage III melanoma.” Expert Review in Dermatology 2011; 6(6) 567-75
* Co-first authorship